TIME-DEPENDENT CHANGES IN SERUM 3-ALPHA-ANDROSTANEDIOL GLUCURONIDE CORRELATE WITH HIRSUTISM SCORES AFTER OVARIAN SUPPRESSION

被引：7

作者：

CARMINA, E ^{[1
]}

STANCZYK, FZ ^{[1
]}

GENTZCHEIN, E ^{[1
]}

LOBO, RA ^{[1
]}

机构：

[1] UNIV PALERMO,CATTEDRA ENDOCRINOL,PALERMO,ITALY

来源：

GYNECOLOGICAL ENDOCRINOLOGY | 1995年 / 9卷 / 03期

关键词：

HIRSUTISM; 3-ALPHA-ANDROSTANEDIOL GLUCURONIDE; ANDROSTERONE GLUCURONIDE; POLYCYSTIC OVARY SYNDROME;

D O I：

10.3109/09513599509160449

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

The clinical utility of serum 3 alpha-androstanediol glucuronide level has been controversial. Among the concerns regarding its lack of utility has been the finding that suppression of serum 3 alpha-androstanediol glucuronide does not occur readily with treatment. We hypothesized that because the treatment of hirsutism requires a prolonged duration, a longer observation period is required for changes in serum 3 alpha-androstanediol glucuronide to be measured. Therefore, we studied the clinical and hormonal changes in II women treated for hirsutism with a gonadotropin-releasing hormone agonist (GnRH-a) for 1 year. A progressive reduction in Ferriman-Gallwey stores occurred, which was significant at 6 weeks and was maximal at 12 months. Serum 3 alpha-androstanediol glucuronide and another peripheral marker, androsterone glucuronide, also fell commensurately. While there was no correlation at 3 months, by 6 weeks a significant correlation had occurred between the suppression in Ferriman-Gallwey scores and the suppression of serum 3 alpha-androstanediol glucuronide and androsterone glucuronide. The suppression of these steroids also correlated with the suppression of nan-sex hormone-binding globulin-bound testosterone. These data confirm that markers of peripheral androgen action, particularly serum 3 alpha-androstanediol glucuronide, reflect the clinical manifestation of hirsutism. However, it appears that modifications in peripheral androgen activity (presumably through 5 alpha-reductase activity) are time-dependent, and that serum markers reflect changes after 6 months of treatment.

引用

页码：215 / 220

页数：6

共 18 条

[1] Horton R., Hawks D., Lobo R.A., 3α, 17β-androstenediol glucuronide in plasma: a marker of androgen action in idiopathic hirsutism, J. Clin. Invest, 69, pp. 1203-1206, (1982)
[2] Matteri R.K., Stanczyk F.Z., Gentzchein E., Delgado C., Lobo R.A., Androgen sulfate and glucuronide conjugates in nonhirsute and hirsute women with polycystic ovary syndrome, Am. J. Obstet. Gynecol, 161, pp. 1704-1709, (1989)
[3] Lobo R.A., Hirsutism, alopecia and acne, Principles and Practice of Endocrinology and Metabolism, pp. 834-838, (1990)
[4] Matteri R.K., Stanczyk F.Z., Cassidenti D.L., Paulson R.J., Lobo R.A., The ovarian contribution to peripherally derived serum C19 conjugates, J. Clin. Endocrinol. Metab, 75, pp. 768-772, (1992)
[5] Rittmaster R.B., Androgen conjugates: physiology and clinical significance, Endocr. Rev, 14, pp. 121-132, (1993)
[6] Rittmaster R.S., Thompson D.L., Effect of leuprolide and dexamethasone on hair growth and hormone levels in hirsute women. The relative importance of the ovary and the adrenal in the pathogenesis of hirsutism, J. Clin. Endocrinol. Metab, 70, pp. 1096-1102, (1990)
[7] Vermeulen A., Giagulli V.A., Physiopathology of plasma androstanediol glucuronide, J. Steroid Biochem. Mol. Biol, 39, pp. 829-833, (1991)
[8] Stanczyk F.Z., Moltz L., Schwartz V., Lobo R.A., Dexamethasone (DEX) suppressibility and adrenal and ovarian venous effluents of 5α-reduced C19 conjugates in women, (1990)
[9] Carmina E., Gentzchein E., Stanczyk F.Z., Lobo R.A., Substrate dependency of C19 conjugates in hirsute hyperandrogenic women and the influence of adrenal androgen, Hum. Reprod, 10, pp. 299-303, (1995)
[10] Zwicker H., Rittmaster R.S., Androsterone sulfate: physiology and clinical significance in hirsute women, J. Clin. Endocrinol. Metab, 76, pp. 112-116, (1993)

← 1 2 →